Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 21st World Congress on Gastrointestinal Cancer /
Entrectinib in NTRK-fusion positive gastrointestinal cancers

3rd - 7th Jul 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.07.19
Views: 528

Prof Salvatore Siena - Università degli Studi di Milano Statale, Milan, Italy

Prof Salvatore Siena speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about the use of entrectinib in NTRK-fusion positive gastrointestinal cancers.

The results were taken from an integrated analysis based on patients in three trials - STARTRK-2, STARTRK-1 and ALKA-372-001.

Prof Siena reports that entrectinib was very well tolerated and induced clinically meaningful, durable responses in select patients.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation